What is this study trying to find out about hepatorenal syndrome?

This study aims to analyze outcomes in patients with hepatorenal syndrome by comparing different treatment methods such as vasoconstrictors, albumin, and renal support therapies. Researchers want to understand how these treatments impact patient health over time. The study is conducted by Methodist Health System to improve knowledge about managing this condition.

Who may be eligible for this hepatorenal syndrome clinical trial?

Adults aged 18 to 85 diagnosed with hepatorenal syndrome who were hospitalized between April 2019 and April 2023 may be eligible. Both males and females can participate. Important factors include specific kidney function changes and absence of other kidney diseases. Please review eligibility criteria for more details.

Is there any cost to participate in this hepatorenal syndrome clinical trial?

Study-related care, including all data analysis and review, is provided at no cost. However, personal travel or other expenses are not applicable since this is a retrospective study reviewing past records. Participants will not need to attend any visits or procedures.

Actively Recruiting

Age: 18Years - 85Years

All Genders

ID06095440

Retrospective Study of Treatment Outcomes for Hepatorenal Syndrome Patients at Methodist Dallas Medical Center

Led by Methodist Health System · Updated on 2026-05-01

500

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Hepatorenal syndrome HRS is a condition causing acute kidney injury in patients with liver disease, often due to circulatory changes from vasodilators like nitric oxide. It presents with elevated serum creatinine, benign urine sediment, and low urine sodium. The study evaluates outcomes in patients with HRS by comparing various treatment methods to better understand their effects and support treatment decisions. The research is a retrospective analysis of patients with HRS, focusing on treatments including vasoconstrictors, albumin, continuous renal replacement therapy CRRT, Molecular Adsorbent Recirculating System MARS, and transjugular intrahepatic portosystemic shunts TIPS. CRRT is considered especially for patients with severe electrolyte imbalances and can serve as a bridge to liver transplantation, although it carries risks such as low blood pressure and cardiac events. TIPS may improve kidney function by reducing portal pressure. Participants are patients over 18 hospitalized between April 2019 and April 2023 diagnosed with HRS. Researchers will review medical records to assess treatment outcomes, focusing on primary outcomes for HRS-AKI patients over four years and post-transplant mortality rates. The study involves no interventions or additional procedures beyond data analysis. The total participation involves reviewing historical data, with no direct patient involvement or follow-up.

CONDITIONS

Brief Title

A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center

Who Can Participate

Age: 18Years - 85Years

All Genders

Eligibility Criteria

You may qualify if you...

Patients older than 18 years hospitalized between April 1, 2019, and April 1, 2023
Diagnosed with HRS-AKI or developed HRS during hospital stay
Presence of cirrhosis, acute liver failure, or acute-on-chronic liver failure
Increase in serum creatinine of 0.3 mg/dL within 48 hours or 50% from baseline, or low urine output for at least 6 hours
No response after at least 2 days of diuretic withdrawal and albumin treatment
Absence of shock
No current or recent use of nephrotoxic drugs
No parenchymal kidney disease
Suggestion of renal vasoconstriction with fractional excretion of sodium less than 0.2%

You will not qualify if you...

Patients younger than 18 years
Hospitalized patients between April 1, 2019, and April 1, 2023 without a diagnosis of HRS-AKI

Research Team

Colette Ngo Ndjom, MS

Loretta W Bedell, MPH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here